Feasibility and Outcome of Cyberknife® Precision Hypofractionated Radiosurgery for the Curative Management of Non-Small Cell Lung Cancer
- To establish the maximum tolerated dose of CyberKnife® hypofractionated stereotactic
radiosurgery in patients with medically inoperable, stage I or II non-small cell lung
- To establish the relationship between PET response and local control and survival using
fludeoxyglucose F 18 PET/CT imaging before treatment and at 1, 3, 6, and 12 months
OUTLINE: Patients undergo placement of 3 gold fiducial markers by CT-guidance or
bronchoscopy. Patients then undergo CyberKnife® hypofractionated stereotactic radiosurgery
over 45-120 minutes twice weekly for 2 weeks.
Patients undergo fludeoxyglucose F 18 PET/CT scan at baseline and at 1, 3, 6, and 12 months
after completion of treatment.
After completion of study treatment, patients are followed periodically for up to 4 years.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To establish the maximally tolerated dose of CyberKnife® radiosurgery in patients with medically inoperable clinical Tl-3 N0 M0 NSCLC
Lisa A. Kachnic, MD
Boston Medical Center
United States: Food and Drug Administration
|Boston University Cancer Research Center||Boston, Massachusetts 02118|